Alcon ACL

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. Leadership changes at Novartis

      Headlines

      Wed, 9 Apr 2014

      CEO Joe Jimenez taps Jeff George to run Alcon and Richard Francis to run Sandoz. Mr. George has been ..... the last five years managing Sandoz. He takes the helm of Alcon on May 1. Mr. Francis joins the company after a 13-year

    2. Novartis names new heads for Alcon and Sandoz divisions

      Headlines

      Wed, 9 Apr 2014

      ZURICH, April 9 (Reuters) - Swiss drugmaker Novartis has appointed new heads of its eyecare business Alcon and generics division Sandoz, the group's second and third largest businesses after pharmaceuticals.

    3. BRIEF-Barr Labs did not infringe two Alcon patents, but patent claims are not invalid -- US appeals court

      Headlines

      Tue, 18 Mar 2014

      March 18 (Reuters) - * U.S. appeals court upholds finding that barr laboratories

    4. Nestle Swaps L'Oreal Stake for Skin Care Business; We Like the Firm's Moves into Health and Wellness

      Commentary

      Tue, 11 Feb 2014

      deal are strategic acquisitions in the health and wellness space, and debt repayment. When Nestle sold its 52% stake in Alcon in 2010, it used the cash to cut its debt levels. Total debt/EBITDA fell from 1.5 times at the end of 2009 to 0

    5. New Morningstar Analyst Report for Novartis AG

      Stock Reports

      Wed, 18 Dec 2013

      Further, the much larger acquisition of Alcon in the rapidly growing eye-care market ..... looking at the entire company, including Alcon , we project an average 3% annual ..... looking at the entire company, including Alcon , we project an average 3% annual

    6. Novartis Posts Slightly Weak 3Q as Manufacturing Costs Continue, but No Change to Fair Value

      Commentary

      Thu, 25 Oct 2012

      Outside the drug group, Novartis' remaining divisions posted slight declines, with the exception of a minor gain at the Alcon group. We believe manufacturing issues are weighing on consumer and generic drug sales. While resolutions to manufacturing

    7. Simplicity Is a Virtue for This Fund

      Video Reports

      Thu, 21 Jun 2012

      always has regulatory challenges from the payers. But the firm has a really superb franchise in its eye-care business, Alcon . Its pharmaceutical business is doing quite well. So when you look with the cash flows that the business generates, it's

      Alcon found at 10:25

      But the firm has a really superb franchise in its eye-care business, Alcon . Its pharmaceutical business is doing quite well. So when you look with the cash flows that the business generates, it's really trading
    8. Nestle Scores in Deal to Acquire Pfizer's Nutrition Business

      Commentary

      Mon, 23 Apr 2012

      growth opportunity is reflected in the rich multiple Nestle is paying for the investment. When Nestle sold its stake in Alcon to Novartis NVS for $28 billion pretax, we argued that it should invest the cash in extending its footprint in emerging

    9. BBH Core Select 2nd Quarter 2011 Commentary

      Headlines

      Wed, 20 Jul 2011

      billion acquisition of eye-care leader Alcon (0.0%)*, Johnson & Johnson ..... On balance, we view the Novartis/ Alcon and Johnson & Johnson/Synthes transactions ..... arbitrage activity relating to the Alcon merger. In June, after Novartis’s share

    10. Wall Street Breakfast: Must-Know News

      Headlines

      Tue, 19 Jul 2011

      climbed 12% to $2.7B and sales jumped 27% to $14.9B, boosted by the recent acquisition of eye-care specialist Alcon , the rapid growth of recently launched drugs, and cost cutting. Novartis expects demand for its new treatments to offset

    « Prev12345Next »
    Content Partners